Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20 Virtual Scientific Progral

NEXT STORY
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference
PREV STORY
New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

author_avatar
NASDAQ Market News

Global Home Infusion Therapy Market Is Expected to Reach USD 43.62 Billion by 2027 : Fior Markets

author_avatar
NASDAQ Market News

Overview Of COVID-19’s Positive Impact On The Drug Delivery Devices Market

author_avatar
NASDAQ Market News